S. Mark Wilkinson, Olivier Aerts, Tove Agner, Magnus Bruze, Richard Brans, Caterina Foti, Ana Maria Giménez-Arnau, Luca Stingeni, Cecilia Svedman
{"title":"对含甲基丙烯酸酯的指甲产品的接触性过敏:缺乏欧盟立法的影响。代表欧洲环境接触性皮炎研究小组(EECDRG)进行的审计。","authors":"S. Mark Wilkinson, Olivier Aerts, Tove Agner, Magnus Bruze, Richard Brans, Caterina Foti, Ana Maria Giménez-Arnau, Luca Stingeni, Cecilia Svedman","doi":"10.1111/cod.14745","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>There is a current fashion for the use of methacrylate-containing nail cosmetics that can induce allergic contact dermatitis. European Union (EU) legislation was introduced in 2021 that had the aim of preventing its development.</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>To assess prevalence and exposures causing contact allergy to 2-hydroxyethyl methacrylate (HEMA) prior to and following implementation of the legislation.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective audit was conducted by 7 European centres patch testing to HEMA prior to the legislation and for 2 years afterwards.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 26 297 patients were tested to HEMA in the baseline series between 2016 and 2023. The prevalence of contact allergy to HEMA from all sources amongst females was 2.82% compared to 0.34% amongst males.</p>\n \n <p>The prevalence of nail related contact allergy rose from 0.91% in 2016 (2 centres) to: 0.99% in 2017 (3 centres); 1.24% in 2018 (5 centres); 1.23% in 2019 (6 centres); 1.36% in 2020 (7 centres); 1.30% in 2021 (7 centres); 1.52% in 2022 (7 centres) and 1.98% in 2023 (7 centres).</p>\n \n <p>Contact allergy to HEMA from exposure to nail cosmetics accounted for 3.4% of all occupational skin disease.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>EU legislation appears not to have had the intended impact on controlling allergic contact dermatitis from methacrylates in nail cosmetics. There is an urgent need to revisit Scientific Committee on Consumer Safety (SCCS) opinion to reconsider exposure to methacrylates and cross-reactions between them. A strategy needs to be developed and implemented to better control the current outbreak.</p>\n </section>\n </div>","PeriodicalId":10527,"journal":{"name":"Contact Dermatitis","volume":"92 4","pages":"283-290"},"PeriodicalIF":4.8000,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Contact Allergy to Methacrylate Containing Nail Products: Lack of Impact of EU Legislation. An Audit on Behalf of the European Environmental Contact Dermatitis Research Group (EECDRG)\",\"authors\":\"S. Mark Wilkinson, Olivier Aerts, Tove Agner, Magnus Bruze, Richard Brans, Caterina Foti, Ana Maria Giménez-Arnau, Luca Stingeni, Cecilia Svedman\",\"doi\":\"10.1111/cod.14745\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>There is a current fashion for the use of methacrylate-containing nail cosmetics that can induce allergic contact dermatitis. European Union (EU) legislation was introduced in 2021 that had the aim of preventing its development.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objectives</h3>\\n \\n <p>To assess prevalence and exposures causing contact allergy to 2-hydroxyethyl methacrylate (HEMA) prior to and following implementation of the legislation.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>A retrospective audit was conducted by 7 European centres patch testing to HEMA prior to the legislation and for 2 years afterwards.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>A total of 26 297 patients were tested to HEMA in the baseline series between 2016 and 2023. The prevalence of contact allergy to HEMA from all sources amongst females was 2.82% compared to 0.34% amongst males.</p>\\n \\n <p>The prevalence of nail related contact allergy rose from 0.91% in 2016 (2 centres) to: 0.99% in 2017 (3 centres); 1.24% in 2018 (5 centres); 1.23% in 2019 (6 centres); 1.36% in 2020 (7 centres); 1.30% in 2021 (7 centres); 1.52% in 2022 (7 centres) and 1.98% in 2023 (7 centres).</p>\\n \\n <p>Contact allergy to HEMA from exposure to nail cosmetics accounted for 3.4% of all occupational skin disease.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>EU legislation appears not to have had the intended impact on controlling allergic contact dermatitis from methacrylates in nail cosmetics. There is an urgent need to revisit Scientific Committee on Consumer Safety (SCCS) opinion to reconsider exposure to methacrylates and cross-reactions between them. A strategy needs to be developed and implemented to better control the current outbreak.</p>\\n </section>\\n </div>\",\"PeriodicalId\":10527,\"journal\":{\"name\":\"Contact Dermatitis\",\"volume\":\"92 4\",\"pages\":\"283-290\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-12-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Contact Dermatitis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cod.14745\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contact Dermatitis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cod.14745","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
Contact Allergy to Methacrylate Containing Nail Products: Lack of Impact of EU Legislation. An Audit on Behalf of the European Environmental Contact Dermatitis Research Group (EECDRG)
Background
There is a current fashion for the use of methacrylate-containing nail cosmetics that can induce allergic contact dermatitis. European Union (EU) legislation was introduced in 2021 that had the aim of preventing its development.
Objectives
To assess prevalence and exposures causing contact allergy to 2-hydroxyethyl methacrylate (HEMA) prior to and following implementation of the legislation.
Methods
A retrospective audit was conducted by 7 European centres patch testing to HEMA prior to the legislation and for 2 years afterwards.
Results
A total of 26 297 patients were tested to HEMA in the baseline series between 2016 and 2023. The prevalence of contact allergy to HEMA from all sources amongst females was 2.82% compared to 0.34% amongst males.
The prevalence of nail related contact allergy rose from 0.91% in 2016 (2 centres) to: 0.99% in 2017 (3 centres); 1.24% in 2018 (5 centres); 1.23% in 2019 (6 centres); 1.36% in 2020 (7 centres); 1.30% in 2021 (7 centres); 1.52% in 2022 (7 centres) and 1.98% in 2023 (7 centres).
Contact allergy to HEMA from exposure to nail cosmetics accounted for 3.4% of all occupational skin disease.
Conclusions
EU legislation appears not to have had the intended impact on controlling allergic contact dermatitis from methacrylates in nail cosmetics. There is an urgent need to revisit Scientific Committee on Consumer Safety (SCCS) opinion to reconsider exposure to methacrylates and cross-reactions between them. A strategy needs to be developed and implemented to better control the current outbreak.
期刊介绍:
Contact Dermatitis is designed primarily as a journal for clinicians who are interested in various aspects of environmental dermatitis. This includes both allergic and irritant (toxic) types of contact dermatitis, occupational (industrial) dermatitis and consumers" dermatitis from such products as cosmetics and toiletries. The journal aims at promoting and maintaining communication among dermatologists, industrial physicians, allergists and clinical immunologists, as well as chemists and research workers involved in industry and the production of consumer goods. Papers are invited on clinical observations, diagnosis and methods of investigation of patients, therapeutic measures, organisation and legislation relating to the control of occupational and consumers".